COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS

• US 20100183718A1
• Filed: 06/25/2008
• Published: 07/22/2010
• Est. Priority Date: 06/26/2007
• Status: Abandoned Application

• Current Assignee: Ceva Sante Animale SA
• Original Assignee: Ceva Sante Animale SA
• Inventors: Bernay, Florence, Guyonnet, Jerome, Ovaert, Patricia
• Application Number:
  US12/666,026
• Publication Number:
  US 20100183718A1
• Time in Patent Office: Days
• US Class Current: 424/479
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/50 Pyridazines; Hydrogenated pyridazines
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/585 containing lactone rings, e.g. oxandrolone, bufalin
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/42 for decreasing, blocking or antagonising the activity of mineralocorticosteroids
• CPC Class Codes: A61P 7/12 Antidiuretics, e.g. drugs for diabetes insipidus ADH A61P5/10
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications

Abstract

The invention relates to novel compositions including an aldosterone antagonist and administered according to a predetermined dosage for treating heart deficiency in non-human mammals.

Claims

1-18. -18. (canceled)

19. A method of treating and/or preventing non-human mammal subjects affected by heart failure comprising administering an aldosterone antagonist, and a pharmaceutically acceptable vehicle to said subject, wherein said aldosterone antagonist is administered in an efficient therapeutic dose ranging between 1.5 and 5 mg/kg/day, 1.8 and 5 mg/kg/day, 1.5 and 4 mg/kg/day, or 1.5 and 3 mg/kg/day in a single take.

20. The method of claim 19, wherein said aldosterone antagonist is administered in an efficient therapeutic dose ranging between 2 and 5 mg/kg/day, in a single take.

21. The method of claim 20, wherein said aldosterone antagonist is administered in an efficient therapeutic dose of approximately 2 mg/kg/day in a single take or 4 mg/kg/day in a single take.

22. The method of claim 19, wherein said aldosterone antagonist is the spironolactone, the eplerenone, a derivative or a metabolite thereof.

23. The method of claim 19, wherein said aldosterone antagonist is administered to said subject in combination with at least one standard therapy for the treatment of heart failure.

24. The method of claim 23, wherein said standard therapy is an angiotensin converting enzyme inhibitor, an angiotensin II AT-1-receptor antagonist, an inotrope, an inodilator, a vasodilator, a diuretic, a digitalic drug, a beta blocker or a calcic antagonist.

25. The method of claim 24, wherein the angiotensin converting enzyme inhibitor is present in an efficient therapeutic dose of approximately 0.1 to 0.6 mg/kg/day, and preferably of approximately 0.25 to 0.5 mg/kg/day.

26. The method of claim 24, wherein the angiotensin converting enzyme inhibitor is alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, idrapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, perindropilat, temocapril, trandolapril, ceranapril, moexipril, quinaprilat, spirapril, a salt or a pharmaceutically acceptable ester thereof.

27. The method of claim 26, wherein benazepril is administered to said subject in a dose of 0.25 mg/kg/day and enalapril in a dose of 0.5 mg/kg/day.

28. The method of claim 24, wherein the inotrope or inodilator is the pimobendane or the levosimendane.

29. The method of claim 28, wherein pimobendane or levosimendane is present in an efficient therapeutic dose.

30. The method of claim 29, wherein claim pimobendane or levosimendane is administered orally or by injection.

31. The method of claim 30, wherein said aldosterone antagonist is spironolactone and is administered to said subject in a dose of 2 mg/kg/day only in a single take.

32. The method of claim 31, wherein the spironolactone is administered to said subject in combination with an efficient quantity of benazepril or enalapril.

33. The method of claim 32, wherein benazepril is administered in a dose of 0.25 mg/kg/day and enalapril is administered in a dose of 0.5 mg/kg/day.

34. The method of claim 31, wherein the spironolactone is administered to said subject in combination with an efficient quantity of pimobendane or levosimendane.

36. The method of claim 19, wherein said subject affected by heart failure is a dog, a cat or a horse.

37. The method of claim 19, wherein administration is performed via oral, nasal, intradermic, cutaneous, or parenteral route.

38. The method of claim 19, wherein an aldosterone antagonist and pharmaceutically acceptable vehicle is administered is in the form of a liquid solution, suspension, solid or semi-solid, powders, pellets, capsules, granules, sugar-coated pills, gelules, sprays, cachets, pills, tablets, pastes, implants or gels.